Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation
Status:
Completed
Trial end date:
2014-08-21
Target enrollment:
Participant gender:
Summary
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells
are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess
the safety and effectiveness of low molecular weight sulfated dextran (LMW-SD) on
post-transplant islet function in people with type 1 diabetes who have responded to intensive
insulin therapy.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Clinical Islet Transplantation Consortium National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)